|
[1] BOSETTI C,TURATI F,LA VECCHIA C.Hepatocellular carcinoma epidemiology[J].Best Pract Res Cl Ga,2014,28(5):753-770.
|
|
[2]HERNANDEZ-GEA V,TOFFANIN S,FRIEDMAN SL,et al.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma[J].Gastroenterology,2013,144(3):512-527.
|
|
[3]WU YJ,GUO JS.An inflammatory and fibrotic microenvironment promotes hepatocellular carcinogenesis[J].Chin J Hepatol,2014,22(2):156-158.(in Chinese)吴玉婧,郭津生.肝脏炎症及纤维化微环境与肝癌发生关系的研究进展[J].中华肝脏病杂志,2014,22(2):156-158.
|
|
[4]MASUZAKI R,TATEISHI R,YOSHIDA H,et al.Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography[J].Hepatology,2009,49(6):1954-1961.
|
|
[5]SCHRADER J,GORDON-WALKER TT,AUCOTT RL,et al.Matrix stiffness modulates proliferation,chemotherapeutic response,and dormancy in hepatocellular carcinoma cells[J].Hepatology,2011,53(4):1192-1205.
|
|
[6]LI Z,DRANOFF JA,CHAN EP,et al.Transforming growth factorbeta and substrate stiffness regulate portal fibroblast activation in culture[J].Hepatology,2007,46(4):1246-1256.
|
|
[7] LIU Y,POON RT,LI Q,et al.Both antiangiogenesis-and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584[J].Cancer Res,2005,65(9):3691-3699.
|
|
[8]ZHU AX,DUDA DG,SAHANI DV,et al.HCC and angiogenesis:possible targets and future directions[J].Nat Rev Clin Oncol,2011,8(5):292-301.
|
|
[9]BUDHU A,WANG XW.The role of cytokines in hepatocellular carcinoma[J].J Leukoc Biol,2006,80:1197-1213.
|
|
[10]TILG H,WILMER A,VOGEL W,et al.Serum levels of cytokines in chronic liver diseases[J].Gastroenterology,1992,103(1):264-274.
|
|
[11]KRYCZEK I,LANGE A,MOTTRAM P,et al.CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers[J].Cancer Res,2005,65(2):465-472.
|
|
[12]ABOU-SHADY M,BAER HU,FRIESS H,et al.Transforming growth factor betas and their signalling receptors in human hepatocellular carcinoma[J].Am J Surg,1999,177(3):209-215.
|
|
[13]de LUCA A,CAROTENUTO A,RACHIGLIO A,et al.The role of the EGFR signalling in tumor microenvironment[J].J Cell Physiol,2008,214:559-567.
|
|
[14]WALLACE MC,FRIEDMAN SL.Hepatic fibrosis and the microenvironment:fertile soil for hepatocellular carcinoma development[J].Gene Expr,2014,16(2):77-84.
|
|
[15]SANCHO-BRU P,JUEZ E,MORENO M,et al.Hepatocarcinoma cells stimulate the growth,migration and expression of pro-angiogenic genes in human hepatic stellate cells[J].Liver Int,2010,30(1):31-41.
|
|
[16]ROMBOUTS K,CARLONI V.The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma[J].Fibrogenesis Tissue Repair,2013,6(1):17.
|
|
[17]ZHAO W,SU W,KUANG P,et al.The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma[J].Int J Oncol,2012,41(2):457-464.
|
|
[18]KESAR V,ODIN JA.Toll-like receptors and liver disease[J].Liver International,2014,34(2):184-196.
|
|
[19]GUO J,FRIEDMAN SL.Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis[J].Fibrogenesis Tissue Repair,2010,3:21
|
|
[20]WANG X,SUN R,WEI H,et al.High-mobility group box 1(HMGB1)-Toll-like receptor(TLR)4-interleukin(IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis:interaction of gamma delta T cells with macrophages[J].Hepatology,2013,57(1):373-384.
|
|
[21]PETRASEK J,CSAK T,GANZ M,et al.Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis[J].J Gastroenterol Hepatol,2013,28(Suppl 1):93-98.
|
|
[22] ZARE-BIDAKI M,TSUKIYAMA-KOHARA K,KAZEMI ARABABADI M.Toll-like receptor 4 and hepatitis B infection:molecular mechanisms and pathogenesis[J].Viral Immunology,2014,27(7):321-326.
|
|
[23]HOWELL J,ANGUS P,GOW P,et al.Toll-like receptors in hepatitis C infection:Implications for pathogenesis and treatment[J].J Gastroenterol Hepatol,2013,28(5):766-776.
|
|
[24]ZHAI Y,SHEN XD,O'CONNELL R,et al.Cutting edge:TLR4 activation mediates liver ischemia/reperfusion inflammatory response via ifn regulatory factor 3-dependent myd88-independent pathway[J].J Immunol,2004,173(12):7115-7119.
|
|
[25]ZHAO J,ZHAO S,ZHOU G,et al.Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis[J].Scand J Gastroenterol,2011,46(4):485-494.
|
|
[26]SHIMODA S,HARADA K,NIIRO H,et al.Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis[J].Hepatology,2011,53(4):1270-1281.
|
|
[27]KARRAR A,BROOME U,SODERGREN T,et al.Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis[J].Gastroenterology,2007,132(4):1504-1514.
|
|
[28]GUO J,LOKE J,ZHENG F,et al.Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of toll-like receptor 4to hepatic stellate cell responses[J].Hepatology,2009,49(3):960-968.
|
|
[29]XU D,WANG X,YAN S,et al.Interaction of PTPRO and TLR4signaling in hepatocellular carcinoma[J].Tumor Biology,2014,35(10):10267-10273.
|
|
[30]WANG Z,YAN J,LIN H,et al.Toll-like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice[J].Hepatology,2013,57(5):1869-1881.
|
DownLoad: